USRM (US Stem Cell) LT-Debt-to-Total-Asset: 10.03 (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell LT-Debt-to-Total-Asset?

US Stem Cell USRM -99.00% 12 LT-Debt-to-Total-Asset is 10.03 as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. US Stem Cell's long-term debt to total assests ratio for the quarter that ended in Dec. 2022 was 10.03.

US Stem Cell's long-term debt to total assets ratio declined from Dec. 2021 (14.16) to Dec. 2022 (10.03). It may suggest that US Stem Cell is progressively becoming less dependent on debt to grow their business.

US Stem Cell  (OTCPK:USRM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

US Stem Cell LT-Debt-to-Total-Asset Related Terms

US Stem Cell LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for US Stem Cell's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell LT-Debt-to-Total-Asset Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 8.40 8.64 14.16 10.03

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.16 5.01 9.89 4.02 10.03
USRM
12GF Score
US Stem Cell Inc USRM
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell LT-Debt-to-Total-Asset Calculation

US Stem Cell's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0.682/0.068
=10.03

US Stem Cell's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (Q: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )/Total Assets (Q: Dec. 2022 )
=0.682/0.068
=10.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 10.03 mean?
US Stem Cell (USRM) has a LT-Debt-to-Total-Asset of 10.03 as of Dec. 2022. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's LT-Debt-to-Total-Asset too high?
US Stem Cell's current LT-Debt-to-Total-Asset is 10.03. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's LT-Debt-to-Total-Asset compare to NOVNQ and RGRX?
US Stem Cell's LT-Debt-to-Total-Asset of 10.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on US Stem Cell and its competitors. US Stem Cell's current LT-Debt-to-Total-Asset is 10.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current LT-Debt-to-Total-Asset of 10.03. The current LT-Debt-to-Total-Asset is 10.03. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For US Stem Cell (USRM), the current LT-Debt-to-Total-Asset is 10.03 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price